BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
BioXcel Therapeutics (Nasdaq: BTAI), a biopharmaceutical company focused on AI-driven medicine development in neuroscience and immuno-oncology, has announced its plan to release second quarter 2024 financial results on August 6, 2024, before U.S. financial markets open. The company will host a conference call and webcast at 8:00 AM ET on the same day to discuss the results and provide a business update.
Investors and interested parties can access the webcast link under the 'News/Events' section of BioXcel's website. For those unable to attend live, a replay will be available for 90 days following the event. This announcement highlights BioXcel's commitment to transparency and shareholder communication.
BioXcel Therapeutics (Nasdaq: BTAI), una compagnia biofarmaceutica focalizzata sullo sviluppo di medicinali guidati dall'AI in neuroscienze e immuno-oncologia, ha annunciato il piano di rilasciare i risultati finanziari del secondo trimestre 2024 il 6 agosto 2024, prima dell'apertura dei mercati finanziari statunitensi. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 8:00 AM ET nello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale.
Investitori e parti interessate possono accedere al link della trasmissione nella sezione 'News/Events' del sito web di BioXcel. Per coloro che non possono partecipare dal vivo, sarà disponibile una registrazione per 90 giorni dopo l'evento. Questo annuncio evidenzia l'impegno di BioXcel per la trasparenza e la comunicazione con gli azionisti.
BioXcel Therapeutics (Nasdaq: BTAI), una compañía biofarmacéutica centrada en el desarrollo de medicina impulsada por IA en neurociencia e inmuno-oncología, ha anunciado su plan de publicar los resultados financieros del segundo trimestre de 2024 el 6 de agosto de 2024, antes de la apertura de los mercados financieros en EE.UU. La empresa llevará a cabo una conferencia telefónica y una transmisión por web a las 8:00 AM ET el mismo día para discutir los resultados y proporcionar una actualización empresarial.
Los inversores y partes interesadas pueden acceder al enlace de la transmisión en la sección 'News/Events' del sitio web de BioXcel. Para aquellos que no puedan asistir en vivo, habrá una repetición disponible durante 90 días después del evento. Este anuncio resalta el compromiso de BioXcel con la transparencia y la comunicación con los accionistas.
BioXcel Therapeutics (Nasdaq: BTAI)는 신경과학 및 면역 종양학 분야에서 AI 기반 의약품 개발에 중점을 둔 바이오 제약 회사로, 2024년 2분기 재무 결과를 2024년 8월 6일 미국 금융 시장 개장 이전에 발표할 계획이라고 발표했습니다. 회사는 동일한 날 오전 8시 ET에 회의 전화 및 웹 캐스트를 개최하여 결과를 논의하고 비즈니스 업데이트를 제공할 것입니다.
투자자 및 관심 있는 사람들은 BioXcel 웹사이트의 'News/Events' 섹션에서 웹 캐스트 링크에 접근할 수 있습니다. 생방송에 참석할 수 없는 경우, 이벤트 후 90일 동안 재생이 제공됩니다. 이 발표는 BioXcel의 투명성과 주주 커뮤니케이션에 대한 헌신을 강조합니다.
BioXcel Therapeutics (Nasdaq: BTAI), une entreprise biopharmaceutique axée sur le développement de médicaments alimentés par l'IA en neuroscience et en immuno-oncologie, a annoncé son intention de publier les résultats financiers du deuxième trimestre 2024 le 6 août 2024, avant l'ouverture des marchés financiers américains. La société organisera une conférence téléphonique et un webinaire le même jour à 8h00 ET pour discuter des résultats et fournir une mise à jour sur les activités.
Les investisseurs et les parties intéressées peuvent accéder au lien du webinaire dans la section 'News/Events' du site web de BioXcel. Pour ceux qui ne peuvent pas assister en direct, une rediffusion sera disponible pendant 90 jours après l'événement. Cet annonce met en lumière l'engagement de BioXcel envers la transparence et la communication avec ses actionnaires.
BioXcel Therapeutics (Nasdaq: BTAI), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von AI-gesteuerten Arzneimitteln in der Neurowissenschaft und Immunonkologie konzentriert, hat seinen Plan angekündigt, die Finanzergebnisse für das zweite Quartal 2024 am 6. August 2024 vor der Eröffnung der US-Finanzmärkte zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate zu geben.
Investoren und Interessierte können den Webcast-Link im Bereich 'News/Events' auf der Website von BioXcel finden. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung für 90 Tage nach der Veranstaltung verfügbar sein. Diese Ankündigung unterstreicht BioXcels Engagement für Transparenz und Kommunikation mit den Aktionären.
- None.
- None.
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the open of the U.S. financial markets. The Company’s management team will also host a conference call and webcast at 8:00 AM ET that day to discuss these results and provide a general business update.
| Conference Call and Webcast Details | |
| Date/Time: | Tuesday, August 6, 2024, at 8:00 AM ET |
| Participant Dial-In: | 877-407-5795 / +1 201-689-8722 |
The webcast link will be accessible under “News/Events” on the Investors & Media page of the Company's website at bioxceltherapeutics.com.
| Replay* | |
| Replay Dial-In: | 877-660-6853 / 201-612-7415 |
| Access ID: | 13747782 |
*Available for 90 days following live event
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, the date and time of the release of Company’s second quarter 2024 financial results and related conference call. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at www.bioxceltherapeutics.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contact Information
Corporate
BioXcel Therapeutics
Erik Kopp
1.203.494.7062
ekopp@bioxceltherapeutics.com
Media
Russo Partners
David Schull
1.858-717-2310
David.schull@russopartnersllc.com
Scott Stachowiak
1.646-942-5630
Scott.stachowiak@russopartnersllc.com
Source: BioXcel Therapeutics, Inc.
FAQ
When will BioXcel Therapeutics (BTAI) release its Q2 2024 financial results?
What time is BioXcel Therapeutics' (BTAI) Q2 2024 earnings call scheduled for?
How can investors access BioXcel Therapeutics' (BTAI) Q2 2024 earnings call?
Where can I find the webcast link for BioXcel Therapeutics' (BTAI) Q2 2024 earnings call?
